1. Osteoglycin prevents the development of age-related diastolic dysfunction during pressure overload by reducing cardiac fibrosis and inflammation
- Author
-
Ward Heggermont, Stephane Heymans, Javier Díez, Marieke Rienks, Uwe Himmelreich, Jolanda van der Velden, Sophie Deckx, Rick van Leeuwen, Tom Dresselaers, Arantxa González, Anna-Pia Papageorgiou, Paolo Carai, Wies Lommen, Physiology, ACS - Heart failure & arrhythmias, RS: CARIM - R2 - Cardiac function and failure, Promovendi CD, Cardiologie, RS: CARIM - R2.02 - Cardiomyopathy, and MUMC+: MA Med Staf Spec Cardiologie (9)
- Subjects
0301 basic medicine ,Cardiac function curve ,Aging ,medicine.medical_specialty ,Cardiac fibrosis ,Interleukin-1beta ,Diastole ,030204 cardiovascular system & hematology ,DISEASE ,Mice ,03 medical and health sciences ,0302 clinical medicine ,Fibrosis ,Internal medicine ,Animals ,Humans ,Medicine ,LEUCINE-RICH PROTEOGLYCANS ,Molecular Biology ,Cells, Cultured ,Chemokine CCL2 ,Pressure overload ,Matrix ,Osteoglycin ,ABNORMALITIES ,business.industry ,Angiotensin II ,Macrophages ,Myocardium ,STIFFNESS ,Aortic Valve Stenosis ,Fibroblasts ,Intercellular Adhesion Molecule-1 ,medicine.disease ,COLLAGEN ,Hypertensive heart disease ,PREVALENCE ,030104 developmental biology ,Endocrinology ,PRESERVED EJECTION FRACTION ,MYOCARDIAL-INFARCTION ,Heart failure ,Hypertension ,Diastolic dysfunction ,HEART-FAILURE ,Intercellular Signaling Peptides and Proteins ,Myocardial fibrosis ,business - Abstract
The small leucine-rich proteoglycan osteoglycin has been implicated in matrix homeostasis in different organs, including the ischemic heart. However, whether osteoglycin modulates cardiac hypertrophy, fibrosis or inflammation in hypertensive heart disease and during aging remains unknown. Angiotensin-II-induced pressure overload increases cardiac osteoglycin expression, concomitant with the onset of inflammation and extracellular matrix deposition. Interestingly aging led to decreased cardiac levels of osteoglycin, yet absence of osteoglycin did not affect organ structure or cardiac function up to the age of 18 months. However, Angiotensin-II infusion in combination with aging resulted in exaggerated cardiac fibrosis and inflammation in the osteoglycin null mice as compared to wild-type mice, resulting in increased diastolic dysfunction as determined by magnetic resonance imaging. In vitro, stimulation of bone marrow derived macrophages from osteoglycin null mice with Angiotensin-II resulted in significantly higher levels of ICAM-1 as well as pro-inflammatory cytokines and chemokines IL-1 beta and MCP-1 as compared to WT cells. Further, stimulation of human cardiac fibroblasts with osteoglycin reduced cell proliferation and inhibited TGF-beta induced collagen gene expression. In mouse cardiac tissue, osteoglycin expression inversely correlated with TGF-beta expression and in cardiac biopsies of aortic stenosis patients, osteoglycin expression is significantly higher than in control biopsies. Interestingly, osteoglycin levels were higher in patients with less severe myocardial fibrosis and overall in the aortic stenosis patients osteoglycin levels negatively correlated with collagen content in the myocardium. In conclusion, osteoglycin expression is increased in the heart in response to pressure overload and its absence results in increased cardiac inflammation and fibrosis resulting in increased diastolic dysfunction. (C) 2017 Elsevier B.V. All rights reserved.
- Published
- 2018